-

11:12:59 AM

MYNZ Stock News

MYNZ - Mainz Biomed B.V.

03/02/22 3:01 AM

Nasdaq : MYNZ

low float

Mainz Biomed and Partners Join International Awareness Campaign for Colorectal Cancer Awareness Month

Mainz Biomed N.V. (NASDAQ:MYNZ)

RHEA-AI

neutral

02/23/22 3:01 AM

Nasdaq : MYNZ

low float

Mainz Biomed Provides U.S. Regulatory Review Update for ColoAlert

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the

RHEA-AI

very positive

02/14/22 3:01 AM

Nasdaq : MYNZ

low float

Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, Mönchengladbach

Laboratory Stein is part of the Limbach Group, which is the largest network of laboratories in Germany and one of the largest networks of laboratories in Europe Laboratory MVZ Dr. Stein + Kollegen processes over five million samples annually with a team of 500 employees that includes biologists,

RHEA-AI

very positive

02/09/22 3:01 AM

Nasdaq : MYNZ

managementlow float

Mainz Biomed Appoints Oncology Expert Dr. Rainer Metzger to Strategic Advisory Board

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular

RHEA-AI

very positive

02/04/22 3:01 AM

Nasdaq : MYNZ

clinical triallow float

Mainz Biomed Initiates Clinical Study to Evaluate Integrating Novel mRNA Biomarkers Into ColoAlert

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz

RHEA-AI

very positive

01/28/22 4:05 PM

Nasdaq : MYNZ

offeringlow float

Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular

RHEA-AI

neutral

01/27/22 3:01 AM

Nasdaq : MYNZ

managementlow float

Mainz Biomed Appoints Steve Quinn as VP Business Development

RHEA-AI

very positive

01/25/22 8:00 PM

Nasdaq : MYNZ

low float

Mainz Biomed Announces Pricing of Follow-on Offering

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the pricing of its underwritten public follow-on

RHEA-AI

neutral

01/19/22 3:01 AM

Nasdaq : MYNZ

clinical triallow float

Mainz Biomed Engages DCN Dx to Support Clinical Study Evaluating Novel mRNA Biomarkers for Potential Integration into ColoAlert

Mainz Biomed N.V.

RHEA-AI

very positive

01/12/22 3:01 AM

Nasdaq : MYNZ

managementlow float

Mainz Biomed Appoints Michele Pedrocchi, Former Head of Roche Diagnostics Business Development, to Strategic Advisory Board

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Michele Pedrocchi to its

RHEA-AI

neutral

Prev 1 2 3 4 Next